Tissue engineering and regenerative medicine · 2026
Polydeoxyribonucleotide (PDRN) in Dentistry: Narrative Review for Mechanisms and Emerging Clinical Applications.
СтатьяОбзорНазвание и аннотация: Перевод в очереди
Обработка статьи · этапы, ошибки и управление
Загрузка состояния…
Ошибки и ограничения
История · было → стало
Состояние обновляется каждые 5 секунд, пока блок открыт. Процент показывается только там, где известен объём работы. Пауза останавливает продолжение этапа; текущий запрос к источнику может завершиться.
Ku Jeong-Kui, Yun Pil-Young, Jeong Yeong Kon
Аннотация
BACKGROUND: Polydeoxyribonucleotide (PDRN) has emerged as a promising and cost-effective biological agent in regenerative medicine due to its anti-inflammatory, angiogenic, and tissue-regenerative properties.
METHODS: This review outlines the mechanisms of action of PDRN, namely activation of the A2A receptor and nucleotide provision via the salvage pathway, and summarizes its biological roles in dental regeneration together with current preclinical and clinical evidence.
RESULTS: In dentistry, PDRN has been shown to enhance osteogenesis and vascularization when used with bone graft scaffolds, to exert anti-inflammatory and chondroprotective effects in temporomandibular joint disorders, and to modulate pain pathways in neuropathic conditions. It has also demonstrated adjunctive benefits in managing inflammatory oral diseases such as peri-implantitis and medication-related osteonecrosis of the jaw, where its dual regenerative and anti-inflammatory actions support both soft- and hard-tissue healing.
CONCLUSION: Although these findings highlight broad therapeutic potential, current evidence remains limited. Most reports derive from preclinical experiments or small-scale clinical studies, and well-designed randomized controlled trials are needed to validate efficacy of PDRN and define its optimal clinical indications in evidence-based dental protocols.
METHODS: This review outlines the mechanisms of action of PDRN, namely activation of the A2A receptor and nucleotide provision via the salvage pathway, and summarizes its biological roles in dental regeneration together with current preclinical and clinical evidence.
RESULTS: In dentistry, PDRN has been shown to enhance osteogenesis and vascularization when used with bone graft scaffolds, to exert anti-inflammatory and chondroprotective effects in temporomandibular joint disorders, and to modulate pain pathways in neuropathic conditions. It has also demonstrated adjunctive benefits in managing inflammatory oral diseases such as peri-implantitis and medication-related osteonecrosis of the jaw, where its dual regenerative and anti-inflammatory actions support both soft- and hard-tissue healing.
CONCLUSION: Although these findings highlight broad therapeutic potential, current evidence remains limited. Most reports derive from preclinical experiments or small-scale clinical studies, and well-designed randomized controlled trials are needed to validate efficacy of PDRN and define its optimal clinical indications in evidence-based dental protocols.